Apoptin, a small protein from chicken anemia virus, has attracted great attention, because it specifically kills tumor cells while leaving normal cells unharmed. The subcellular localization of apoptin appears to be crucial for this tumor-selective activity. In normal cells, apoptin resides in the cytoplasm, whereas in cancerous cells it translocates into the nucleus. The nuclear translocation of apoptin is largely controlled by its phosphorylation. In tumor cells, apoptin causes the nuclear accumulation of survival kinases including Akt and is phosphorylated by CDK2. Thereby, apoptin redirects survival signals into cell death responses. Apoptin also binds as a multimeric complex to DNA and interacts with several nuclear targets, such as the anaphasepromoting complex, resulting in a G2/M phase arrest. The proapoptotic signal of apoptin is then transduced from the nucleus to cytoplasm by Nur77, which triggers a p53-independent mitochondrial death pathway. In this review, we summarize recent discoveries of apoptin's mechanism of action that might provide intriguing insights for the development of novel tumor-selective anticancer drugs.
Introduction
Apoptin is a small apoptosis-inducing protein derived from chicken anemia virus (CAV), which belongs to the Gyrovirus genus and Circoviridae family and contains a single, minus-strand circular DNA. CAV infects young chickens with the highest infectivity and mortality on the hatch day, whereas chickens become completely resistant to CAV-related death after about two weeks of hatching [1] . Hematopoietic cells in the bone marrow and T-cell precursors in the thymus are the major targets for CAV infection. The early infection of hematopoietic precursors results in the reduction of erythroid precursor cells and megakaryocytes. This eventually leads to anemia and thrombocytopenia, causing intramuscular hemorrhage and death. The infection can be propagated within the flock both vertically and horizontally. Interestingly, in chickens carrying tumors induced by Rous sarcoma virus the intra-tumoral expression of apoptin causes tumor regression [2] . Thus, the coevolution of CAV and the host may offer benefits to latently infected chickens.
Sequences in the 5′-nontranscribed region of the CAV genome function as promoter/enhancers [3] . The CAV genome contains three partially overlapping open reading frames which produce a polycistronic unspliced RNA encoding three different proteins [1, [4] [5] [6] . All proteins are expressed in CAV-infected cells [5, 6] . VP1 is a 51-kDa capsid protein and VP2 a 24-kDa dual specificity phosphatase. Importantly, the induction of apoptosis by CAV has been attributed to VP3, a 14-kDa non-structural protein, which is therefore also referred to as apoptin [5, 7, 8] . Apoptin alone can induce apoptosis in a broad range of transformed and cancer cells but not in nontransformed or primary cells [9, 10] . Recent data link apoptin's complex mode of action to various cellular proteins, which play prominent roles in both cell proliferation and cell death. It was reported that late in infection, three other CAV mRNAs are synthesized due to splicing events [11] . One of them encodes a putative truncated apoptin protein consisting of the first 58 amino acids only. The significance of these additional putative gene products for cell death and other CAV manifestations is still unclear.
111-121 [12, 13] . In addition, apoptin contains a putative nuclear export sequence (NES) at residues 97-105 ( Fig. 1 ). These recognition sequences drive the shuttling of apoptin in and out of the nucleus. Apoptin also harbors a short hydrophobic leucine-rich stretch (aa [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] that is required for self-association as well as binding of promyelocytic leukemia protein and other interaction partners [9, 14] . It is interesting to note that the biologically active form of recombinant apoptin can form noncovalently attached globular multimers consisting of 30-40 monomers [15] . The formation of this multimeric complex appears to be facilitated through the interaction of the proline-rich hydrophobic regions in the N-terminus (aa 1-69) of each monomer [16] . The C-terminal tip of each monomer, on the other hand, contains a NLS with an accessible phosphorylation site (Thr-108), which allows for its interaction with other proteins and for modification by kinases. Microinjection of apoptin multimers into the cytoplasm of tumor cells reveals that apoptin complexes translocate to the nucleus resulting in apoptotic death [15] . This confirms that apoptin multimers retain biological activity. Unfortunately, a crystal structure of apoptin or its multimeric complex is not available.
Induction of apoptosis in tumor cells by apoptin
Apoptin has been reported to induce the selective death of cell lines derived from diverse human tumors including melanoma, hepatoma, lymphoma, cholangiocarcinoma, colon carcinoma, breast and lung cancer and others [14, 17] . Indeed, to date more than 70 human tumor cell lines were shown to be susceptible to apoptin, whereas apoptin does not induce apoptosis in a variety of normal cells, including human endothelial cells, hepatocytes and hematopoietic stem cells. Thus, the sensitivity to apoptin presumably depends on alterations related to the transformed status of the cell [14] . Apoptin induces apoptosis not only in tumor cells, but also in SV40-transformed fibroblasts or UV-irradiated cells from individuals with hereditary cancer-prone syndromes [18, 19] . There is only one single report of toxicity towards some non-cancerous cells [20] . Nonetheless, this study provided cell death data only for a fetal cell type (i.e. secondary cultures of human lung fibroblasts) and not for other non-transformed cell types. This raises the possibility that apoptin selectively affects normal cells at embryonic stage, similar to apoptin's toxicity in young but not adult chickens. However, the safety of apoptin is underlined by the fact that continuous expression of apoptin under the H2-K b promoter in transgenic mice does not interfere with lymphocyte development and proliferation [21] . This is in contrast to the deleterious effects on the immune system observed in young chickens upon CAV infection.
In addition to reports that apoptin effectively induces tumorspecific apoptosis in animal models, intra-tumoral injection of recombinant apoptin into nude mice with xenografted human hepatoma cells reduces tumor growth and improves tumor regression within a week of administration [22] . There are additional reports that apoptin can enhance tumor size reduction. In fact, when apoptin is used in combination with other chemotherapeutics, tumor regression is more dramatic compared to conditions when apoptin or chemotherapeutic drugs are administered alone [7, 24] .
Mechanisms of apoptin-mediated cell death
The mechanisms of cell death induced by apoptin are not clearly understood, although there is a consensus on the existence of certain molecular events. One of the key properties of apoptin is its ability to induce tumor-specific cell apoptosis independently of p53 [25] . Thus, apoptin is similarly effective in killing tumor cells that are p53-deficient or either express wildtype or mutant p53.
Apoptosis is typically mediated by intracellular cysteine proteases, called caspases, that function as initiators and executioners of the apoptotic process [26, 27] . The activation of caspases is accomplished by two major signaling routes: the extrinsic death receptor and the intrinsic mitochondrial pathway. In the extrinsic pathway, ligation of death receptors by their cognate ligands triggers the recruitment of the adaptor FADD and initiator caspase-8 into a death-inducing signaling complex. The mitochondrial pathway is initiated by the release of cytochrome c into the cytosol, a process that is tightly regulated by pro-and anti-apoptotic proteins of the Bcl-2 family. Once released, cytochrome c binds to the adapter protein Apaf-1, which enables the activation of the initiator caspase-9 in a high-molecularweight complex, called the apoptosome. Both pathways then converge at the activation of downstream effector caspases, leading to cell death via the cleavage of several cellular substrates [26] [27] [28] .
It is now well established that apoptin expression results in the activation of caspases [29] . Apoptin-mediated cell death is however independent of death receptors, as cells deficient in FADD or caspase-8, the key regulators of the extrinsic apoptotic pathway [30] , remain sensitive to apoptin. Moreover, blocking of death receptor CD95 with neutralizing antibodies does not affect apoptin-induced cell death. In contrast to components of the death receptor pathway, apoptinmediated apoptosis is strongly influenced by regulators of the mitochondrial pathway, as for instance a deficiency of Apaf-1 strongly protects tumor cells. Furthermore, apoptin triggers cytochrome c release and the activation of caspase-9 [31] .
Interestingly, the role of anti-apoptotic Bcl-2 in apoptin-mediated cell death is still a matter of debate. Some research groups reported that apoptin-mediated cell death is independent of the Bcl-2 status, and that co-expression of apoptin and Bcl-2 even accelerates cell death [32] [33] [34] . In contrast, Burek et al. [31] showed that both Bcl-2 and Bcl-x L inhibit apoptosis triggered by apoptin in several tumor cell lines. Notably, the proapoptotic Bcl-2 member Bax sensitizes cells to apoptin-induced apoptosis, whereas cells devoid of Bax are strongly protected [31] . Thus, at least in several cell types, apoptin-induced cell death is regulated by pro-and anti-apoptotic Bcl-2 proteins and involves the release of cytochrome c and activation of effector caspases. The apparent controversy as to the role of Bcl-2 proteins may arise from the differential involvement of Nur77, a member of the steroid receptor family, in apoptin-induced cell death. It has been shown that Nur77 can bind to Bcl-2 and change its properties from an anti-apoptotic to a proapoptotic molecule, leading to the activation of mitochondrial death pathway [35] . Because Nur77 is expressed in different cell types at very varying levels, this might explain the opposite effects of Bcl-2 on apoptin-induced cell death.
Maddika et al. [30] indeed proposed a role of Nur77 in apoptinmediated apoptosis (Fig. 2) . Phosphorylated Nur77 appears to transmit apoptotic signal from the nucleus to mitochondria, as it was shuttled from the nucleus to the cytoplasm upon transient expression of apoptin. Moreover, RNAi-mediated downregulation of Nur77 strongly protected against apoptin-triggered apoptosis [30] . It is presently unclear which kinase phosphorylates Nur77, however, Akt that is strongly activated upon apoptin treatment is a viable candidate. Upon transfer to cytoplasm, Nur77 may directly or indirectly cause cytochrome c release and activation of the apoptosome-dependent death pathway.
Apoptin-interacting molecules
The cellular localization of apoptin plays crucial role for its selective toxicity [12, 13] . However, the targeted translocation of apoptin into the nucleus is not sufficient to induce apoptosis in primary cells [12] . This finding suggests that for its tumor-specific toxicity apoptin presumably requires additional interaction partners that activate specific signaling pathways in cancer cells. Indeed, a number of molecules have been described to interact with apoptin and appear to be important for the nuclear localization of apoptin or its tumor-selective cytotoxicity (Table 1) .
A recent report [36] provides evidence that apoptin interacts with peptidyl-prolyl isomerase-like 3 (Ppil3). Ppil3 belongs to the cyclophilin family and shares 46% identity to cyclophilin A. Members of this family catalyze the cis-trans isomerization of peptidyl-prolyl imidic bonds and play a role in mitochondrial maintenance, cell cycle progression and apoptosis. The study showed that siRNA-mediated depletion of Pipl3 leads to the migration of apoptin from cytoplasm to Fig. 2 . Proposed mechanism of action of apoptin in tumor cells. Upon heterologous expression or administration of cell-permeable constructs, apoptin associates with the regulatory subunit of PI3K resulting in its constitutive activation, which leads to the sustained activation and nuclear translocation of Akt. The nuclear Akt activates CDK2 by both direct phosphorylation and indirect mechanisms including the proteasome-dependent degradation of p27 Kip1 . The activated CDK2 phosphorylates apoptin at Thr-108 and thereby enforces its nuclear accumulation in cancer cells. In the nucleus, apoptin can associate with different interaction partners including DEDAF, Nmi, APC/C and PML. A still unknown apoptintriggered event results in the phosphorylation of Nur77 and its nuclear export. In the cytoplasm Nur77 is known to modulate Bcl-2 proteins, for instance by converting Bcl-2 from an anti-apoptotic to a proapoptotic molecule. This and additional events might induce apoptin-triggered apoptosis by the mitochondrial pathway of caspase activation. the nucleus. Interestingly, proline-109 in apoptin was essential for the Ppil3-dependent cytoplasmic localization of apoptin [36] . These findings shed a new light on the regulation of apoptin's cellular localization.
Hippi, a protein interacting with huntington-interacting protein 1 (Hip 1), is also a binding partner for apoptin [37] . The Hippi-Hip1 complex can recruit caspase-8 and regulates apoptotic cell demise in Huntington's disease. In non-cancerous cells, apoptin colocalizes with Hippi in the cytoplasm, whereas in tumor cells apoptin migrates to the nucleus while Hippi remains in the cytoplasm [37] . The C-terminus region of apoptin is vital for the interaction with Hippi. As mentioned above, however, apoptin-mediated cell death is not compromised by a genetic deficiency of caspase-8 [30] . Nevertheless, the results suggest that association of apoptin with cytoplasmic Hippi or Ppil3 may play a role in sequestering apoptin in cytoplasm and preventing apoptosis of normal primary cells.
Employing a yeast two-hybrid approach with apoptin as bait, NMyc-interacting protein (Nmi) has been found to associate with apoptin [38] . It is an interferon-inducible protein that can interact with transcription factors of Myc family. Nmi-like proteins enhance the activity of Myc proteins that are involved in cell proliferation, differentiation as well as in apoptosis. The interaction of apoptin and Nmi has been proposed to account for the tumor specificity of apoptin's cytotoxicity, because Nmi is only expressed at low levels in normal tissues but highly upregulated in leukemia cell lines. Apoptin has been hypothesized to switch the Nmi/Myc-mediated transforming activity to an apoptotic activity. However, no functional analyses have been provided as yet, and the restricted expression pattern of Nmi does not explain the broad antitumor activity of apoptin.
Teodoro et al. [39] have shown that apoptin associates with APC1, a subunit of anaphase-promoting complex/cyclosome (APC/C) and thereby inhibits the ubiquitin ligase function of APC/C. This interaction is present in cancer cells but is absent in non-cancerous cells, which suggests another possible mechanism for the tumor-selective action of apoptin. Overexpression of apoptin or RNAi-mediated depletion of APC1 subunit induces apoptosis in p53-null tumor cells, suggesting that apoptin may interfere with the APC/C pathway through binding to APC1. These experiments provide evidence that APC/C may serve as a potential target for the development of novel anticancer therapies.
Due to its basic structure apoptin binds to naked DNA, preferentially to heterochromatin. Biophysical studies revealed that bacterially expressed apoptin forms active protein multimers consisting of [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] monomers [15] . These apoptin multimers in turn can bind to DNA and cooperatively form distinct superstructures consisting of 20 apoptin multimers and approximately 3 kb DNA [16] . Whether apoptin's binding to DNA results in transcriptional events is unknown. The finding that apoptin does neither act as a transcriptional repressor, at least in simple reporter gene assays, nor requires de novo macromolecular synthesis for apoptosis induction would, however, argue against this possibility [12] .
Apoptin can also interact with a proapoptotic protein, called death effector domain-associated factor (DEDAF). DEDAF associates with death effector domain-containing proapoptotic proteins and plays a role in transcriptional regulation [40] . Similar to apoptin, transient overexpression of DEDAF can induce cell death in cancer cells, but not in normal cells. The cellular localization of DEDAF is similar to that of apoptin, as both colocalize into the nucleus of tumor cells. Coexpression of apoptin and DEDAF increases the apoptotic death rate as compared to the effects of expression of either of them alone [40] . Nonetheless, whether the interaction of apoptin with DEADF is responsible for apoptin's toxicity awaits further investigation.
Apoptin also interacts with promyelocytic leukemia protein (PML) and localizes in PML nuclear bodies [41] . PML nuclear bodies are ordered protein complexes that associate with the nuclear matrix and play a role in apoptosis, DNA replication, repair, transcription, RNA transport and viral replication [42] . Many proteins residing in PML nuclear bodies, including apoptin, undergo a specific posttranslational modification, called sumoylation. However, the finding that a sumoylation-deficient mutant of apoptin can still trigger apoptosis in wildtype as well as in PML-deficient cells suggest that neither sumoylation nor the interaction with PML are crucial for apoptin's proapoptotic activity. Nevertheless, although apoptin's interaction with PML appears dispensable for apoptosis, it was speculated to be involved in CAV replication [41] . It has also been suggested that apoptin colocalizes with FADD (Fas-associated protein with death domain) and Bcl10, a caspase recruitment domain-containing protein, in cytoplasmic structures, called death effector filaments [20] . Both FADD and Bcl10 are involved in apoptosis signaling by death receptors, though the significance of this colocalization for apoptin-induced cell death is unknown.
Our group recently reported that, through its proline-rich sequence (aa 81-86), apoptin interacts with the SH3 domain of the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K, Fig. 2 ). Class I PI3 kinases play a central role in various regulatory processes, such as cell growth, survival and differentiation. Surprisingly, when Table 1 Apoptin-interacting molecules.
Molecule
Biological effect References DNA Due to its basic structure, apoptin can directly interact with DNA, preferentially with double-stranded DNA and heterochromatin.
[ 16, 59] Akt and PI3K Apoptin interacts with the SH3-domain of the p85 regulatory subunit of PI3K and activates PI3K. This event leads to sustained Akt activation and presumably aids Akt in nuclear translocation.
[ 43, 44] CyclinA-CDK2 CyclinA-CDK2 complex directly phosphorylates apoptin at Thr-108 and contributes to the regulation of its subcellular localization.
[49]
Peptidyl-prolyl isomerase-like 3 (Ppil3) Apoptin's interaction with Ppil3 may favor its cytoplasmic localization. [36] Hip-interacting protein (Hippi) In non-cancerous cells, apoptin colocalizes with Hippi in the cytoplasm, whereas in tumor cells apoptin migrates to the nucleus while Hippi remains in the cytoplasm.
[37]
N-Myc interacting protein (Nmi) The functional significance of apoptin and Nmi interaction is not well understood.
[38] APC1 (subunit of anaphase-promoting complex/cyclosome) Apoptin's interaction with APC1 may lead to mitotic cell cycle arrest and apoptosis. [39] Death effector domain-associated factor (DEDAF)
Coexpression of apoptin and DEDAF increases apoptosis as compared to the effects of either protein alone. [40] Promyelocytic leukemia protein (PML) SUMOylated apoptin interacts with PML in PML nuclear bodies. However, the disruption of the interaction of PML and apoptin does not affect apoptin's cytotoxicity.
[41]
Fas-associated death domain protein (FADD)
Upon overexpression apoptin colocalizes with FADD, a component of the death receptor pathway, in so-called death effector filaments. The significance of this process is unknown.
[20]
Bcll0
Apoptin can colocalize with Bcl10, a regulator of apoptosis and NF-κB activation.
[20] Importin-β1 Importin-β1 aids apoptin's nuclear translocation through the nuclear pore complex. [10, 13] p85 is downregulated, apoptin is shuttled out of the nucleus, thereby imposing a negative regulation of apoptin-induced cell death [43] . Apoptin derivatives devoid of the proline-rich region do not interact with p85, are unable to activate PI3K and show impaired apoptosis induction. Thus, the interaction of apoptin with p85 subunit of PI3K appears to be essential for the cytotoxic activity of apoptin [43] . In addition to p85 regulatory subunit of PI3K, its downstream effector kinase Akt1 was also found as an apoptin-interacting molecule [44] . Although the role of PI3K/Akt pathway in cell survival is well established, there are examples in which PI3K and Akt also promote cell death [45] [46] [47] [48] . Interestingly, as recently reported, the direct interaction of apoptin with Akt1 triggers nuclear trafficking of Akt and initiates apoptosis instead of a survival response [43, 49] . Agents such as etoposide, cisplatin, and interferon-β induce Akt1 phosphorylation that precedes the onset of caspase activation and apoptosis [50, 51] . Importantly, transient activation of Akt1 supports cell survival, whereas its sustained activation leads to apoptosis [52] [53] [54] . These observations therefore support a dual role of PI3K/Akt pathway in cell survival and apoptosis.
Nuclear transfer of apoptin -vital for its apoptotic action
The selective toxicity of apoptin is mainly attributed to its differential subcellular localization in tumor and normal cells (Fig. 3) . Apoptin predominantly localizes to the nucleus of cancer cells, whereas its accumulation in the nucleus is severely impaired in normal cells [12] . Experimental data indicate the nucleo-cytoplasmic shuttling of apoptin is regulated by both the bipartite NLS and the N-terminal NES [10, 12, 13] . The NLS of apoptin is potentially active in both normal and cancer cells, as small amounts of apoptin can translocate to the nucleus in normal cells, albeit with markedly lower efficiency [55, 56] . Notably, a CRM1-regulated NES (aa 97-105) has been identified in apoptin that appears to be active in normal cells but not in tumor cells, and thereby retains apoptin in the cytoplasm of normal cells [10] . Apoptin also contains a leucine-rich sequence (aa [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] that is important for its interaction with PML and other proteins [9, 14] . Mutations that inactivate this sequence stretch not only reduce the ability of apoptin to associate with PML bodies, but also inhibit nuclear accumulation of apoptin in tumor cells.
Apoptin phosphorylation -role in apoptosis induction?
In addition to nuclear targeting signals, the phosphorylation of apoptin is crucial in transducing apoptotic signals in cancer cells. Mapping studies provide evidence that apoptin has a phosphorylation site at threonine-108 (Thr-108) adjacent to the NES [57] . Thr-108 phosphorylation can be detected in vitro and in vivo in cell lines and tumors. Phosphorylation at Thr-108 appears to drive tumor-specific nuclear accumulation of apoptin via inactivation of the NES. In contrast, two studies reported that Thr-108 phosphorylation only partially affects apoptin's proapoptotic activity, as an apoptin mutant devoid of this phosphorylation site retains the ability to induce apoptosis [43, 58] . Some findings suggest that both N-and C-terminal regions of apoptin have the capacity to bind DNA and induce apoptosis independently, and that Thr-108 phosphorylation is required only for the C-terminus [58, 59] . An apoptin mutant consisting of the first 69 amino acids is mainly located in the cytoplasm of human tumor cells, but harbors a distinct, albeit weaker, proapoptotic activity [12] . Furthermore, there is a cluster of three threonine residues (aa 106-108) within the apoptin sequence. Thus, even though this possibility has not yet been tested experimentally, it is conceivable that mutation of Thr-108 may still allow for the phosphorylation of apoptin at the adjacent threonine residues.
Due to the importance of apoptin phosphorylation for its tumorspecific action, the apoptin kinase has intensively been sought for a long time. We could recently identify the mitogenic cyclin-dependent kinase CDK2 as the principal kinase that directly phosphorylates apoptin at Thr-108 and is crucially required for apoptin-induced cell death [49] . As mentioned above, an early event of apoptin signaling is the interference with the PI3K/Akt pathway, which does not only result in a very sustained activation but also the nuclear translocation of Akt. This sustained Akt activation is in contrast to the transient stimulation of kinase activity that is normally observed following Akt activation by growth-stimulatory signals. It is therefore likely that the prolonged activation of Akt might result in the phosphorylation of unusual substrates.
During our studies we found that apoptin-induced Akt stimulation results in a strong activation of CDK2, which is normally a S-phase kinase involved in cycle progression [49] . Interestingly, pharmacological inhibitors as well as dominant-negative mutants of PI3K and Akt not only inhibited CDK2 activation, but also protected cells from apoptin-induced cell death. The Akt-mediated activation of CDK2 was caused by two mechanisms, including the direct phosphorylation of CDK2 and the phosphorylation-induced degradation of its inhibitor p27 Kip1 (Fig. 2) . Furthermore, cyclin A-but not cyclin E-associated CDK2 was responsible for apoptin phosphorylation at Thr-108 as well as its tumor-specific localization. The crucial role of CDK2 for the biological activity of apoptin was further substantiated by the finding that CDK2 inhibitors as well as the genetic deficiency of CDK2 strongly protected cells against apoptin-induced apoptosis [49] . These unexpected findings therefore suggest that apoptin can convert mitogenic pathways into cell death responses, which likely account for its tumorspecific activity. Interestingly, a sustained activation of Akt in nucleus, unlike the transient activation induced by growth factors at the cell membrane, has been implicated in other cell death pathways. For instance, prolonged nuclear Akt/CDK2 activation does not protect but sensitizes tumor cells for apoptosis induced by anticancer agents such as methotrexate and docetaxel [23] . Also, in primary breast tumor cells an elevated basal CDK2 activity has been found to correlate with the sensitivity to paclitaxel [60] . In addition, elevated CDK2 activity has been implicated in apoptosis in some other conditions including negative selection of thymocytes [61] . Aberrant activation of CDK2 might therefore cause disturbance of cell cycle progression and cell death. These observations not only decipher mechanisms of apoptin-induced cell death, but also provide novel insights for the selective killing of tumor cells. Diverse regulators of the PI3K/Akt pathway are involved in tumorigenesis and are highly active in various types of cancers. Hyperactivation of these pathways is associated with a poor clinical prognosis and contributes to drug resistance. Thus, targeting the PI3K/Akt/CDK2 pathway by apoptin might be responsible for its unique tumor-specific effects. We propose that apoptin 'hijacks' cell survival pathways and redirects them towards induction of cell death, thereby establishing a novel link between cell survival and cell death.
Clinical perspectives of apoptin
The ability of apoptin to induce apoptosis independently of p53 and to switch survival pathways into proapoptotic signaling carries an enormous pharmacological potential. These remarkable features might be directly employed for the use of apoptin in cancer therapy. In addition, targeting of apoptin's interaction partners might be an approach to achieve tumor specificity and to design new antitumor therapies. Several preclinical studies have shown that apoptin improves also the efficacy of traditional therapy, while apoptin itself shows no adverse side effects.
Recent studies demonstrate that downregulation of survivin together with the expression of apoptin significantly increases the percentage of apoptotic cells compared to the effects seen upon survivin loss or apoptin expression alone [62, 63] . Survivin belongs to the family of inhibitors of apoptosis proteins (IAP) and is highly expressed in several tumors. These findings suggest that a combined strategy using apoptin and a downregulation of survivin could be effective in controlling the growth of tumors that are otherwise resistant to traditional chemotherapy. Another study has shown that the combined treatment of tumors with recombinant apoptin and IL-18 induced a strong Th1 response against Lewis lung carcinomas that was associated with a significant inhibition of tumor growth [64] . Similarly, a combined therapeutic approach with recombinant adenovirus expressing apoptin and etoposide showed an additive cytotoxicity on human osteosarcoma U2OS cells [24, 33] . Also, when paclitaxel treatment was combined with apoptin, the survival of p53-positive, p53-negative and p53-mutant cancer cells was compromised at a significantly lower dose of cytotoxic chemotherapy. These observations indicate that apoptin in combination with conventional chemotherapeutic agents offers an effective strategy for cancer treatment [24] .
The tumor-selective cell death by apoptin has now been demonstrated in a great number of tumor cells using various techniques including adenoviral transfer, transient overexpression or introduction of cell-permeable apoptin constructs. Furthermore, several groups have studied the effect of apoptin in different mouse modes. While all these studies confirmed a tumor-specific effect, the most challenging issue is still the development of efficient delivery forms of apoptin at the tumor lesion. Noteborn and colleagues developed a strategy for the use of apoptin in cancer therapy based on adenoviral vectors. A single injection of the apoptin-producing adenovirus in xenografted hepatomas resulted in a considerably delay in tumor growth [22] . Furthermore, in order to increase the transduction efficiency some studies have investigated other viruses. A recent study, for instance, showed that infection with a replication-deficient fowlpox virus containing the apoptin gene resulted in a significant induction of apoptosis in hepatoma cells and, moreover, efficiently repressed the growth of subcutaneous tumors in mice [65] .
Another gene-therapeutic approach to express particular genes of interest into the liver is the use of ligand conjugates of the asialoglycoprotein receptor that is specifically expressed on hepatocytes. Systemic administration of the apoptin gene via the asialoglycoprotein receptor into mice bearing hepatocarcinomas resulted in significant tumor regression, whereas normal hepatocytes were clearly not affected by apoptin gene delivery [66] . In addition, apoptin derivatives could be directly targeted to other tissues, such as brain. In this respect, apoptin conjugates that are taken up by the precursor of heparin-binding epidermal growth factor, also known as the diphtheria toxin receptor, are currently being tested [14] . This receptor is constitutively present at the blood-brain barrier and is strongly upregulated in many tumors, such as glioblastoma.
Several studies have used apoptin derivates coupled to protein transduction domains, including HIV-Tat, which allows for the efficient intracellular delivery of exogenously administered apoptin [20, 30, 43] . However, although apoptin fused to HIV-Tat-derived peptide has been proven to efficiently kill various tumor cell types in culture, its use in preclinical and clinical settings is certainly restricted. Nevertheless, HIV-Tat apoptin could be applied for the treatment of squamous cell carcinoma or precancerous skin lesions. The efficacy of apoptin for the treatment of squamous cell carcinoma has recently been demonstrated in a mouse model using its ectopic expression in primary oral tumor cells [67] . It might be also envisioned to utilize the selective accumulation of apoptin in the nucleus of cancer cells for drug development. Thus, fragments of apoptin could be coupled to radionuclides emitting low energy radioactivity in order induce DNA strand breaks selectively in cancer cells.
Other tumor-selective killer proteins
Beside apoptin, the identification of other proapoptotic proteins with cancer-selective properties raises promises for new drug development. The molecular pathways by which these proteins exert their tumor-selective function are intensively investigated. The cytokine TRAIL, a member of the TNF superfamily, induces apoptotic cell death in a wide variety of tumor cells. Preclinical studies in mice and nonhuman primates demonstrated that TRAIL induces apoptosis in human tumors, whereas no cytotoxicity to normal tissues was found [68] . The susceptibility of tumor cells to TRAIL and the apparent lack of activity of TRAIL in normal cells have led to the proposed use of TRAIL in cancer therapy [69] . Indeed, several phase 1 and 2 studies with TRAIL or TRAIL receptor agonists are in progress in cancer patients.
Interestingly, like apoptin, also the viral protein E4orf4 (adenovirus type 5 E4 open reading frame 4) induces p53-independent cell death in a wide range of tumor but not normal cells upon ectopic expression [70] . In analogy to apoptin, E4orf4 is mainly localized in the nucleus and employs the survival kinase c-Src for its apoptosis signaling [71] . Another similarity between E4orf4 and apoptin is the finding that both proteins obviously target the APC/C complex for their tumorspecific induction of apoptosis. This makes the APC/C complex certainly an attractive target for future anticancer therapeutics. In addition, a proapoptotic protein with structural similarity to apoptin has been identified in some isolates of Torque teno virus (TTV) [72, 73] . This protein, named TTV apoptosis-inducing protein (TAIP), triggers p53-independent apoptosis in hepatocellular carcinoma and other tumor cells, albeit mostly with less potency than apoptin. Unlike apoptin, TAIP is localized in the cytoplasm of transformed cells. Furthermore, the high frequency of TTV in human cancer biopsies suggests an indirect tumor growth-stimulatory role of TTV infection rather than a significant oncosuppressive function [74] .
Another remarkable protein with tumor-specific cytotoxic activity has been isolated from a specific fraction of human milk and is therefore called HAMLET (human α-lactalbumin made lethal to tumor cells). The proapoptotic activity of HAMLET was shown to reside in a molecular complex consisting of the milk protein α-lactalbumin and oleic acid, which results in a change of protein conformation [75] . Similar to apoptin, HAMLET is a partly unfolded globule-like complex. In cancer cells, HAMLET translocates to nuclei and induces p53-independent cell death of tumor cells, but not normal cells. Recently, it was shown that treatment with topical HAMLET has a beneficial effect on the regression of skin papillomas [76] .
Ribonucleases have also attracted considerable attention as specific anticancer agents. Onconase, an amphibian ribonuclease from oocytes of the frog Rana pipiens is of particular interest, because it is cytostatic and cytotoxic to various tumor cells and enhances their sensitivity to a number of cytotoxic agents [77] . Onconase has demonstrated significant efficacy in phase III clinical trials of patients with malignant mesothelioma that failed prior chemotherapy. Onconase's specific mechanism of action is not fully understood, but it seems to target gene regulation by microRNAs [77] . In conclusion, further investigations of apoptin and related proteins with a tumor-specific proapoptotic activity will be important not only for understanding the process of carcinogenesis, but might eventually result in new therapeutic options for anticancer treatment.
